NASH / NAFLD Clinical Trial Landscape

Why NASH/MASH trial monitoring matters in 2026

Non-alcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated steatohepatitis (MASH), affects an estimated 6-8% of the global population and is on track to become the leading cause of liver transplantation in the United States. With the 2024 approval of resmetirom (Rezdiffra) as the first-ever approved NASH/MASH treatment, the field has entered a commercial era — and the pipeline is enormous.

The MASH/NASH clinical development landscape in 2026 is one of the most active in gastroenterology:

• THRβ agonists — resmetirom (approved), MGL-3196 follow-ons, and next-generation thyroid receptor-beta agonists for hepatic fat and fibrosis are in development
• GLP-1 receptor agonists — semaglutide (ESSENCE Phase 3 data read out 2023/24), tirzepatide (GIP/GLP-1), and newer GLP-1 agents showing strong MASH activity; combination trials with anti-fibrotic agents proliferating
• FXR agonists — obeticholic acid (OCA) failed Phase 3 for NASH cirrhosis; next-gen FXR agonists (cilofexor, TERN-101) pursuing differentiated profiles
• Anti-fibrotic agents — ASK1 inhibitors, ACC inhibitors, and anti-LOXL2 antibodies pursuing the anti-fibrotic component that GLP-1 agents alone may not fully address
• Combination strategies — two-drug and three-drug combinations pairing metabolic (GLP-1/THRβ) with anti-fibrotic mechanisms are the major Phase 2/3 trend
• NASH-associated HCC prevention — emerging area targeting high-risk cirrhotic patients

What we monitor for NASH and metabolic liver disease

Our system pulls from the ClinicalTrials.gov API every day. For a NASH/MASH watch profile, you can configure alerts for:

• Condition keywords: "NASH", "NAFLD", "MASH", "metabolic dysfunction-associated steatohepatitis", "nonalcoholic steatohepatitis", "liver fibrosis", "metabolic-associated fatty liver"
• Drug/target keywords: "resmetirom", "THRβ", "semaglutide NASH", "tirzepatide liver", "FXR agonist", "obeticholic acid", "GLP-1 NAFLD", "fibrosis F2 F3" — any drug or mechanism you're tracking
• Phase filter: Phase 1 for early combination programs, Phase 2/3 for competitive commercial intelligence
• Sponsor type: Industry, academic, or all
• Status changes: New registrations, enrollment opens, results postings, and terminations

The post-resmetirom MASH pipeline

Resmetirom's approval validated the MASH field commercially and triggered a race to develop differentiated options. The key competitive dynamics:

• GLP-1 combinations are the dominant strategy: Nearly every company is now testing their primary mechanism paired with a GLP-1 agent. Monitoring these combination trial registrations is essential for competitive positioning
• Anti-fibrotic differentiation: Pure metabolic agents reduce fat but may have limited anti-fibrotic effect. Companies with anti-fibrotic mechanisms (anti-LOXL2, anti-TGFβ, Rho kinase inhibitors) are positioning as combination partners
• Advanced fibrosis (F3/F4) vs. earlier disease (F1/F2): Regulatory endpoints differ; monitoring which trials target which fibrosis stage informs the competitive timeline
• Non-invasive biomarkers: Multiple trials are validating FIB-4, ELF score, and imaging biomarkers as trial endpoints — companies that secure surrogate endpoint approval will accelerate development

Who uses NASH/MASH trial monitoring

• Metabolic disease BD teams — tracking competitor programs in GLP-1, THRβ, FXR, and anti-fibrotic categories
• Hepatology and GI investors — monitoring Phase 2/3 initiations and enrollment in the crowded MASH space
• Hepatologists and gastroenterologists — staying current on available trials for patients with advanced fibrosis or MASH cirrhosis
• Diagnostic companies — tracking trials that use non-invasive biomarkers as primary endpoints, validating their technology
• Academic liver disease researchers — following the commercial landscape alongside investigator-initiated programs

How DataLookout works

We run a direct API connection to ClinicalTrials.gov every morning, collecting all new and updated trials. Our matching engine compares each trial against your profile — condition keywords, drug targets, phase, sponsor type, and study status. Only relevant trials reach your inbox.

Your daily digest includes: trial title, phase, sponsor, current status, enrollment target, primary endpoint, and a direct link to the ClinicalTrials.gov record. No noise, no duplicate alerts.

Pricing

Free: 1 disease/keyword profile, daily change tracking, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, phase and sponsor filters.

Pro — $149/month: Unlimited profiles, priority email delivery, digest frequency options. Best for BD teams and investors.